Skip to main content

Peer Review reports

From: The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer

Original Submission
26 Aug 2008 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
7 Oct 2008 Reviewed Reviewer Report - Weibo Cai
22 Oct 2008 Reviewed Reviewer Report - Cheryl Baker
29 Oct 2008 Reviewed Reviewer Report - Andreas Bikfalvi
Resubmission - Version 3
Submitted Manuscript version 3
18 Nov 2008 Author responded Author comments - Rolf Brekken
14 Nov 2008 Reviewed Reviewer Report - Weibo Cai
Resubmission - Version 4
18 Nov 2008 Submitted Manuscript version 4
Resubmission - Version 5
Submitted Manuscript version 5
24 Nov 2008 Author responded Author comments - Rolf Brekken
Resubmission - Version 6
24 Nov 2008 Submitted Manuscript version 6
Publishing
27 Nov 2008 Editorially accepted
27 Nov 2008 Article published 10.1186/1471-2407-8-352

You can find further information about peer review here.

Back to article page